February 23rd 2023
February 23rd 2023
AHRQ and ECRI Launch New Guideline Assessment Tool
November 26th 2017A new tool developed by the Agency for Healthcare Research and Quality and the ECRI Institute will assess the extent to which a guideline adheres to the Institute of Medicine’s (IOM) standards for trustworthy evidence-based clinical guidelines.
Read More
Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas
November 22nd 2017Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.
Read More
Documenting When a Patient Falls Outside a Recommended Pathway
November 20th 2017Documenting when a patient falls outside of a recommended pathway has the dual benefits of improving the algorithm and helping a provider get reimbursed faster, explained Torrie K. Fields, MPH, senior program manager of Palliative Care Program Design & Implementation for Blue Shield of California.
Watch
Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says
November 17th 2017High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.
Read More
Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC
November 8th 2017Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.
Read More
FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer
November 1st 2017The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.
Read More
70-GS Influences Physician Treatment Guidance for Patients With Early Breast Cancer
October 31st 2017Results of the 70-gene signature assay strongly influence physician's treatment recomendations for patients with early breast cancer who were classified as intermediate risk by the 21-gene assay.
Read More
The Argument for Caution When Judging Industry Payments to Dermatology Clinical Guideline Authors
October 26th 2017After a study reported that physicians who authored dermatology clinical guidelines didn't always fully disclose financial conflicts of interest, the American Academy of Dermatology urged the public to view the findings with caution.
Read More
Updates to Treatment Options During Breast Cancer Awareness Month
October 2nd 2017October is breast cancer awareness month, and as September ended, a new treatment received the FDA’s approval for advanced breast cancer and another was granted priority review for the adjuvant treatment of early breast cancer.
Read More
Physicians Develop Guidelines to Manage CAR T-Cell Toxicity
September 20th 2017Physicians across different institutes who have been involved in clinical trials of chimeric antigen receptor (CAR) T cells in B-cell lymphomas have developed a guideline for monitoring and managing the symptoms associated with this treatment.
Read More
Real-World Data Used to Inform Approval of Low-Dose Cabazitaxel for Prostate Cancer
September 15th 2017Cabazitaxel can now be used at a dose of 20 mg/m2 every 3 weeks in combination with prednisone in patients with metastatic castration-resistant prostate cancer who have received a docetaxel-based treatment regimen.
Read More
First Anticancer Biosimilar Treatment Approved for Multiple Indications
September 14th 2017The FDA has approved bevacizumab-awwb (Mvasi) as a treatment for multiple cancers. The drug has been approved as a biosimilar to its reference biologic, bevacizumab (Avastin), but it has not been approved as an interchangeable product.
Read More